Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation…
Dec 13 
Category: The Business Cocktail
Dec 6
The Business Cocktail
Roche signs Icagen in neuro drug discovery deal worth up to USD 274 Million Roche and Icagen have signed a licensing and collaboration deal regarding ion…
Nov 29 
The Business Cocktail
Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This…
Nov 22 
The Business Cocktail
Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become…
Nov 15 
The Business Cocktail
Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO. A while ago, La Jolla, California-based biotech got off…
Nov 8 
The Business Cocktail
Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics The Gordon and Betty Moore Foundation is putting up money for improving…
Nov 1 
The Business Cocktail
Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup Tango Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with…
Oct 18
The Business Cocktail
Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug…
Oct 11 
The Business Cocktail
Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This…
Oct 4 
The Business Cocktails
Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women’s health based in Massachusetts, United States, is taking…
